Finally, although exploring the existence of PD-L1 could provide strategies to choose immunotherapy for NSCLC, responses to PD-1/PD-L1 antibodies were also noted in NSCLC with low or absent PD-L1 expression. Here, CD274 is linked to non-small cell lung carcinoma.